(Q44955215)

7 December 2017

title

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma (English)

1 reference

7 December 2017

1 reference

3

1 reference

7 December 2017

Michele Milella

1

1 reference

7 December 2017

Alain Gelibter

2

1 reference

7 December 2017

Emilio Bria

4

1 reference

7 December 2017

Enzo Maria Ruggeri

5

1 reference

7 December 2017

Paolo Carlini

6

1 reference

7 December 2017

Paola Malaguti

7

1 reference

7 December 2017

Mario Pellicciotta

8

1 reference

7 December 2017

Edmondo Terzoli

9

1 reference

7 December 2017

Francesco Cognetti

10

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

101

1 reference

7 December 2017

issue

1

1 reference

7 December 2017

page(s)

133-138

1 reference

Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Celecoxib: a specific COX-2 inhibitor with anticancer properties

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Many actions of cyclooxygenase-2 in cellular dynamics and in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Aspirin use and lung, colon, and breast cancer incidence in a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

A prospective study of aspirin use and the risk of pancreatic cancer in women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Cyclooxygenase-2 expression in human pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Review article: current treatment and optimal patient management in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Combining cytotoxic chemotherapy with cyclooxygenase-2 inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20338

7 January 2021

Identifiers

DOI

10.1002/CNCR.20338

1 reference

release_cfw5i3l36re5hdxf57l6jpw5ru

7 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cfw5i3l36re5hdxf57l6jpw5ru

24 November 2022

mapped directly with Wikidata item

1 reference